16 results on '"Saussez, Sven"'
Search Results
2. Validity and Reliability of the French Short Version of the Questionnaire of Olfactory Disorders-Negative Statements (sQOD-NS).
- Author
-
Leclercq, Céline, Chiesa-Estomba, Carlos M., Horoi, Mihaela, Le Bon, Serge D., Hans, Stephane, Distinguin, Lea, Chekkoury-Idrissi, Younes, Circiu, Marta P., Khalife, Mohamad, Saussez, Sven, and Lechien, Jérôme R.
- Subjects
EXPERIMENTAL design ,STATISTICS ,RESEARCH evaluation ,STATISTICAL reliability ,RESEARCH methodology ,RESEARCH methodology evaluation ,VISUAL analog scale ,MANN Whitney U Test ,SEVERITY of illness index ,CRONBACH'S alpha ,QUESTIONNAIRES ,QUALITY of life ,SMELL disorders ,DESCRIPTIVE statistics ,DATA analysis software ,DATA analysis ,STATISTICAL correlation ,FRENCH people - Abstract
Objective: To develop a French Short Version of the Questionnaire of Olfactory Disorders-Negative Statements (Fr-sQOD) to assess the quality of life impairments of patients with olfactory dysfunction (OD). Methods: Patients with OD and controls were enrolled from 2 academic centers. Individuals completed the Fr-sQOD, an OD visual analog scale severity, and the French version of the sinonasal outcome tool-22 (SNOT-22). Cronbach α was used to measure the internal consistency of Fr-sQOD. The reliability and the external validity of Fr-sQOD were assessed through a test–retest approach and by correlating Fr-sQOD with SNOT-22 scores, respectively. The external validity was assessed by correlation analysis between Fr-sQOD and the result of an assessment of the severity of OD on a visual analog scale. Results: Eighty patients completed the evaluations. The internal consistency was adequate (Cronbach α.96), and the test–retest reliability was high in the entire cohort (r
s = 0.877, P <.001). The correlation between Fr-sQOD total scores and the severity of OD was moderate but significant (rs = −0.431; P =.001) supporting an acceptable external validity. Patients with OD had a significantly higher score of Fr-sQOD than healthy individuals (P <.001), indicating a high internal validity. Conclusion: The Fr-sQOD is a reliable and valid self-administered tool in the evaluation of the impact of OD on quality of life of French-speaking patients. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
3. COVID-19: Post-vaccine Smell and Taste Disorders: Report of 6 Cases.
- Author
-
Lechien, Jérôme R., Diallo, Alpha O., Dachy, Bernard, Le Bon, Serge D., Maniaci, Antonino, Vaira, Luigi A., and Saussez, Sven
- Subjects
OTOLARYNGOLOGISTS ,TASTE disorders ,COVID-19 vaccines ,RETROSPECTIVE studies ,ACQUISITION of data ,SMELL disorders ,DESCRIPTIVE statistics ,MEDICAL records - Abstract
Post-vaccine olfactory and gustatory disorders are very rare and were reported in patients who received influenza vaccines. In this article, we report 6 cases of post-coronavirus disease 2019 (COVID-19) vaccine olfactory and gustatory disorders in patients with negative nasal swabs. Precisely, olfactory and gustatory dysfunctions were reported in 5 and 1 patients, respectively. Sense disorders occurred after the first injection of AstraZeneca (n = 4) or the second injection of Pfizer (n = 2) vaccines. In 4 cases, the olfactory or gustatory disorder was confirmed with psychophysical evaluations. The duration of chemosensory dysfunction ranged from 4 to 42 days. None of the patient reported mid- or long-term olfactory or gustatory disorder. The occurrence of olfactory and gustatory dysfunctions in adults benefiting from COVID-19 vaccines is still rare but has to be known by otolaryngologists. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Therapies for COVID-19-Related Persistent Olfactory Disorders: One of the Good Fruits of the Pandemic.
- Author
-
Saussez, Sven, Vaira, Luigi Angelo, De Riu, Giacomo, and Lechien, Jérome R.
- Subjects
SMELL disorders ,COVID-19 pandemic ,PANDEMICS ,PLATELET-rich plasma ,COVID-19 ,OLFACTORY perception - Abstract
10.4193/Rhin21.378 40 Lechien J.R., Le Bon S.D., Saussez S. Platelet-rich plasma injection in the olfactory clefts of COVID-19 patients with long-term olfactory dysfunction. At the beginning of 2021, the scientific community realized the burden of COVID-19-related persistent olfactory disorders (ODs). 10.1007/s12070-021-02749-9. 34277384 26 Kasiri H., Rouhani N., Salehifar E., Ghazaeian M., Fallah S. Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial. This will no longer be possible now that COVID-19 has shed light on this type of disabling dysfunction, raising awareness among patients who will not accept being offered no therapy. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
5. The Trajectories of Olfactory Dysfunction from the First to the Omicron Wave: Are We Getting over it?
- Author
-
Vaira, Luigi Angelo, Lechien, Jérome R., De Riu, Giacomo, and Saussez, Sven
- Subjects
SMELL disorders ,SARS-CoV-2 Omicron variant ,OLFACTORY perception ,COVID-19 ,COVID-19 pandemic - Abstract
10.4193/Rhin21.249 11 Lechien J.R., Vaira L.A., Saussez S. Prevalence and 24-month recovery of olfactory dysfunction in COVID-19 patients: A multicentre prospective study. It has now been two years since the publication in I Pathogens i of our European multicenter study on the prevalence of olfactory dysfunctions (OD) during COVID-19 [[1]]. 10.3390/pathogens10060698 30 Lechien J.R., Vaira L.A., Saussez S. Effectiveness of olfactory training in COVID-19 patients with olfactory dysfunction: A prospective study. 33445604 2 Saniasiaya J., Islam M.A., Abdullah B. Prevalence of olfactory dysfunction in coronavirus disease 2019 (COVID-19): A meta-analysis of 27,492 patients. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
6. Injection of Platelet Rich Plasma in the Olfactory Cleft for COVID-19 Patients With Persistent Olfactory Dysfunction: Description of the Technique.
- Author
-
Lechien, Jerome R. and Saussez, Sven
- Subjects
- *
CENTRIFUGATION , *LOCAL anesthesia , *POST-acute COVID-19 syndrome , *PLATELET-rich plasma , *INJECTIONS , *SMELL , *CONVALESCENCE , *SMELL disorders , *NASAL septum , *PATIENTS' attitudes , *DISEASE risk factors - Abstract
In this paper, we described technique of platelet rich plasma injection into the olfactory cleft in a 22-year-old female with 24-month post–COVID-19 anosmia. The technique starts with the blood extraction and the isolation of PRP through a 10-min centrifugation. The supernatant was injected in nasal regions after a local anesthesia through a 0° rigid optic. Several points of.2–.5 mL were performed in the nasal septum in regard of the head of the middle turbine and in the head of the middle turbine in both sides. The baseline threshold, discrimination, and identification scores were 1, 8, and 0, and the Olfactory Disorder Questionnaire score was 51, respectively. The injection of PRP in olfactory cleft was done without complication and mild pain. The patient perception of recovery of smell sense occurred at 3-week post-injection. From this time, the smell sense progressively improved to the 2-month consultation. At 2-month post-injection, the TDI scores reached 16, 16, and 16 (48), while the Olfactory Disorder Questionnaire was 73. The injection of PRP into the olfactory cleft appears to be a safe and easiness new approach that may improve the recovery of smell sense. Future controlled studies are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. SARS-CoV-2 vaccination may help patients with persistent COVID-19 smell dysfunction.
- Author
-
Lechien, Jerome R, Hopkins, Claire, Vaira, Luigi A, and Saussez, Sven
- Subjects
IMMUNOGLOBULINS ,COVID-19 vaccines ,SMELL ,REGENERATION (Biology) ,ANGIOTENSIN converting enzyme ,SMELL disorders ,AGEUSIA ,INFLAMMATION ,STEM cells ,COVID-19 ,DISEASE risk factors - Abstract
The article proposes a potential hypothesis about the pathophysiological mechanism of olfactory dysfunction (OD) based on some clinical observations. Topics include observation on some patients with persistent COVID-19 OD since the development of vaccination in Western countries, observation on olfactory region abnormalities in imaging study several months after the onset of OD, and analysis of the persistence of OD in COVID-19 patients.
- Published
- 2024
- Full Text
- View/download PDF
8. Predictive factors of smell recovery in a clinical series of 288 coronavirus disease 2019 patients with olfactory dysfunction.
- Author
-
Saussez, Sven, Sharma, Shilpee, Thiriard, Anaïs, Olislagers, Véronique, Vu Duc, Inès, Le Bon, Serge‐D., Khalife, Mohamad, Hans, Stephane, De Riu, Giacomo, Hopkins, Claire, Lechien, Jerome R., Vaira, Luigi A., and Marchant, Arnaud
- Subjects
- *
SMELL disorders , *COVID-19 , *IMMUNOGLOBULIN G , *SARS-CoV-2 , *SMELL , *BIOMARKERS - Abstract
Background and purpose: The aim was to evaluate potential predictive factors of smell recovery in a clinical series of 288 patients presenting olfactory dysfunction (OD) related to coronavirus disease 2019 (COVID‐19). Potential correlations were sought between epidemiological, clinical and immunological characteristics of patients and the persistence of OD at 60 days. Methods: COVID‐19 positive patients presenting OD were prospectively recruited from three European hospitals. Baseline clinical and olfactory evaluations were performed within the first 2 weeks after OD onset and repeated at 30 and 60 days. In a subgroup of patients, anti‐severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antibodies were measured in serum, saliva and nasal secretions at 60 days. Results: A total of 288 COVID‐19 patients with OD were included in the study. Two weeks after the onset of the loss of smell, 52.4% of patients had OD on psychophysical tests, including 113 cases (39.2%) of anosmia and 38 cases (13.2%) of hyposmia. At 60‐day follow‐up, 25.4% of the patients presented persistent OD. There was no significant correlation between sex, age, viral load on nasopharyngeal swab or COVID‐19 severity and poor olfactory outcome. In a subgroup of 63 patients, it was demonstrated that patients with poor olfactory outcomes at 60 days had lower levels of salivary and nasal immunoglobulin G (IgG) and IgG1, but similar levels of antibodies in the serum. Conclusions: No clinical markers predicted the evolution of OD at 60 days. Patients with poor olfactory outcome at 60 days had lower saliva and nasal antibodies, suggesting a role for local immune responses in the persistence of COVID‐19 related OD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Gustatory Dysfunction: A Highly Specific and Smell-Independent Symptom of COVID-19.
- Author
-
Vaira, Luigi Angelo, Lechien, Jerome R., Salzano, Giovanni, Salzano, Francesco Antonio, Maglitto, Fabio, Saussez, Sven, and De Riu, Giacomo
- Subjects
SMELL disorders ,TASTE disorders ,COVID-19 ,SYMPTOMS ,SARS-CoV-2 - Abstract
Chemosensitive dysfunctions are now considered as frequent and early symptoms of coronavirus disease 2019 (COVID-19). In the last few weeks, researchers' greatest efforts have been focusing mainly on the analysis of olfactory disorders, neglecting taste dysfunctions. According to our psychophysical evaluations, it can be inferred that the pathogenesis of taste disorders in COVID-19 patients is largely smell-independent. Moreover, isolated gustatory disorders are highly specific of SARS-CoV-2 infection. For these reasons, it is essential that gustatory dysfunctions, like olfactory disorders, are included in the COVID-19 guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Psychophysical Olfactory Tests and Detection of COVID-19 in Patients With Sudden Onset Olfactory Dysfunction: A Prospective Study.
- Author
-
Lechien, Jerome R., Cabaraux, Pierre, Chiesa-Estomba, Carlos M., Khalife, Mohamad, Plzak, Jan, Hans, Stéphane, Martiny, Delphine, Calvo-Henriquez, Christian, Barillari, Maria R., Hopkins, Claire, and Saussez, Sven
- Subjects
AGE factors in disease ,LONGITUDINAL method ,HEALTH outcome assessment ,POLYMERASE chain reaction ,PSYCHOPHYSICS ,QUESTIONNAIRES ,SMELL ,SMELL disorders ,VIRAL load ,REVERSE transcriptase polymerase chain reaction ,DESCRIPTIVE statistics ,COVID-19 - Abstract
Objective: To investigate the coronavirus disease 2019 (COVID-19) status of patients with initial sudden olfactory anosmia (ISOA) through nasopharyngeal swabs for reverse transcription–polymerase chain reaction (RT-PCR) analysis and to explore their olfactory dysfunctions with psychophysical olfactory evaluation. Methods: A total of 78 ISOA patients were recruited from April 6, 2020, to April 10, 2020, through a public call of University of Mons (Mons, Belgium). Patients benefited from nasopharyngeal swabs and fulfilled the patient-reported outcome questionnaire. Among them, 46 patients performed psychophysical olfactory evaluation using olfactory identification testing. Based on the duration of the ISOA, 2 groups of patients were compared: patients with olfactory dysfunction duration ≤12 days (group 1) and those with duration >12 days (group 2). Results: In group 1, 42 patients (87.5%) had a positive viral load determined by RT-PCR and 6 patients (12.5%) were negative. In group 2, 7 patients (23%) had a positive viral load and 23 patients (77%) were negative. The psychophysical olfactory evaluation reported that anosmia and hyposmia occurred in 24 (52%) and 11 (24%) patients, respectively. Eleven patients were normosmic. The viral load was significantly higher in patients of group 1 compared with those of group 2. Conclusions: Coronavirus disease 2019 was detected in a high proportion of ISOA patients, especially over the first 12 days of olfactory dysfunction. Anosmia is an important symptom to consider in the detection of COVID-19 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019.
- Author
-
Lechien, Jerome R., Chiesa‐Estomba, Carlos M., Place, Sammy, Van Laethem, Yves, Cabaraux, Pierre, Mat, Quentin, Huet, Kathy, Plzak, Jan, Horoi, Mihaela, Hans, Stéphane, Rosaria Barillari, Maria, Cammaroto, Giovanni, Fakhry, Nicolas, Martiny, Delphine, Ayad, Tareck, Jouffe, Lionel, Hopkins, Claire, Saussez, Sven, Blecic, Serge, and De Siati, Daniele R.
- Subjects
COVID-19 ,SMELL disorders ,SEXUAL dimorphism ,SYMPTOMS ,APPETITE loss ,BAYESIAN analysis ,VIRAL pneumonia ,TASTE disorders ,MYALGIA ,AGE distribution ,SEX distribution ,DISEASE prevalence ,EPIDEMICS ,HEADACHE ,PROBABILITY theory ,DISEASE complications - Abstract
Background: The clinical presentation of European patients with mild-to-moderate COVID-19 infection is still unknown.Objective: To study the clinical presentation of COVID-19 in Europe.Methods: Patients with positive diagnosis of COVID-19 were recruited from 18 European hospitals. Epidemiological and clinical data were obtained through a standardized questionnaire. Bayesian analysis was used for analysing the relationship between outcomes.Results: A total of 1,420 patients completed the study (962 females, 30.7% of healthcare workers). The mean age of patients was 39.17 ± 12.09 years. The most common symptoms were headache (70.3%), loss of smell (70.2%), nasal obstruction (67.8%), cough (63.2%), asthenia (63.3%), myalgia (62.5%), rhinorrhea (60.1%), gustatory dysfunction (54.2%) and sore throat (52.9%). Fever was reported by 45.4%. The mean duration of COVID-19 symptoms of mild-to-moderate cured patients was 11.5 ± 5.7 days. The prevalence of symptoms significantly varied according to age and sex. Young patients more frequently had ear, nose and throat complaints, whereas elderly individuals often presented fever, fatigue and loss of appetite. Loss of smell, headache, nasal obstruction and fatigue were more prevalent in female patients. The loss of smell was a key symptom of mild-to-moderate COVID-19 patients and was not associated with nasal obstruction and rhinorrhea. Loss of smell persisted at least 7 days after the disease in 37.5% of cured patients.Conclusion: The clinical presentation of mild-to-moderate COVID-19 substantially varies according to the age and the sex characteristics of patients. Olfactory dysfunction seems to be an important underestimated symptom of mild-to-moderate COVID-19 that needs to be recognized as such by the WHO. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. COVID-19 Reinfection and Second Episodes of Olfactory and Gustatory Dysfunctions: Report of First Cases.
- Author
-
Lechien, Jerome R., Chiesa-Estomba, Carlos M., Vaira, Luigi A., Saussez, Sven, and Hans, Stephane
- Subjects
REVERSE transcriptase polymerase chain reaction ,COVID-19 ,TASTE disorders ,IMMUNOGLOBULINS ,REINFECTION ,SEROLOGY ,SMELL disorders ,WEIGHT loss ,MALNUTRITION ,QUALITY of life ,EATING disorders - Abstract
The article discusses two cases of patients who experienced episodes of olfactory and gustatory dysfunctions after COVID-19 reinfection. Topics mentioned include the prevalence of loss of smell and taste senses in COVID-19 patients, the impact of COVID-19 on the quality of life, the definition of gustatory function, and other symptoms of COVID-19.
- Published
- 2022
- Full Text
- View/download PDF
13. The Effects of Persistent Olfactory and Gustatory Dysfunctions on Quality of Life in Long-COVID-19 Patients.
- Author
-
Vaira, Luigi Angelo, Gessa, Claudia, Deiana, Giovanna, Salzano, Giovanni, Maglitto, Fabio, Lechien, Jerome R., Saussez, Sven, Piombino, Pasquale, Biglio, Andrea, Biglioli, Federico, Boscolo-Rizzo, Paolo, Hopkins, Claire, Parma, Valentina, and De Riu, Giacomo
- Subjects
COVID-19 ,SMELL disorders ,QUALITY of life ,SYMPTOMS ,MYALGIA ,JOINT pain ,MENTAL fatigue - Abstract
(1) Background: Persistent olfactory (POD) and gustatory (PGD) dysfunctions are one of the most frequent symptoms of long-Coronavirus Disease 2019 but their effect on the quality of life (QoL) of patients is still largely unexplored. (2) Methods: An online survey was administered to individuals who reported to have had SARS-CoV-2 infection at least 6 months prior with persisting COVID-19 symptoms (using the COVID symptom index), including ratings of POD and PGD, and their physical (PCS) and mental (MCS) components of quality of life were assessed using the standardized short form 12 questionnaire (SF-12). (3) Results: Responses from 431 unique individuals were included in the analyses. The most frequent persistent symptoms were: fatigue (185 cases, 42.9%), olfactory dysfunction (127 cases, 29.5%), gustatory dysfunction (96 cases, 22.3%) and muscle pain (83 cases, 19.3%). Respondents who reported persisting muscle pain, joint pain, fatigue, headache, gastrointestinal disturbances, and dyspnea had significantly worse PCS. Those experiencing persistent fatigue and dyspnea also showed significantly lower MCS. Respondents reporting POD or PGD showed significantly worse QoL, but only pertaining to the MCS. Multiple regressions predicted MCS based on olfactory and marginally on gustatory ratings, but not PCS. Age significantly affected the prediction of PCS but not MCS, and gender and temporal distance from the COVID-19 diagnosis had no effect. (4) Conclusions: POD and PGD are frequent symptoms of the long-COVID-19 syndrome and significantly reduce QoL, specifically in the mental health component. This evidence should stimulate the establishment of appropriate infrastructure to support individuals with persistent CD, while research on effective therapies scales up. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Anosmia Is a Key Symptom of COVID-19 Infection and Should Be Used as a Diagnostic Tool.
- Author
-
Lechien, Jerome R., Barillari, Maria Rosaria, Jouffe, Lionel, and Saussez, Sven
- Subjects
EPITHELIAL cells ,SMELL disorders ,COVID-19 - Abstract
Based on observations described in our letter, we can draw the following conclusions: (1) anosmia must imperatively be added to the list of specific symptoms of COVID-19 infection, (2) anosmia can serve as a free and specific diagnostic tool for developing countries currently affected by the pandemic, (3) the mechanisms of COVID-19 anosmia seem not to directly involve nasal obstruction but rather seem to be related to damage the olfactory neuroepithelium. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Short-Term Efficacy and Safety of Oral and Nasal Corticosteroids in COVID-19 Patients with Olfactory Dysfunction: A European Multicenter Study.
- Author
-
Saussez, Sven, Vaira, Luigi Angelo, Chiesa-Estomba, Carlos M., Bon, Serge-D. Le, Horoi, Mihaela, Deiana, Giovanna, Petrocelli, Marzia, Boelpaep, Philippe, Salzano, Giovanni, Khalife, Mohamad, Hans, Stephane, De Riu, Giacomo, Hopkins, Claire, and Lechien, Jerome R.
- Subjects
COVID-19 ,SMELL disorders ,COVID-19 treatment ,COVID-19 pandemic ,SAFETY ,RANDOMIZED controlled trials ,COVID-19 testing - Abstract
Background: The objective of this study was to investigate the efficacy and safety of early administration of oral corticosteroids (OC) or nasal corticosteroids (NC) as an add-on to olfactory training (OT) versus OT alone in patients with olfactory dysfunction (OD) related to coronavirus disease 2019 (COVID-19). Methods: Patients with a positive diagnosis of COVID-19 and OD were prospectively recruited from March 22 to December 15, 2020 from 4 European hospitals. Patients had confirmed OD on psychophysical testing. All patients undertook OT, with add-on 10 days of OC (group 1: OC + OT), or 1 month of NC (group 2: NC + OT) or olfactory training alone (group 3: OT). Olfactory evaluations (Sniffin'Sticks tests) were carried out at the time of inclusion, 1 and 2 months after the start of the therapeutic course. Results: A total of 152 hyposmic or anosmic patients completed the study. Group 1, 2 and 3 included 59, 22 and 71 patients, respectively and all patient groups were comparable regarding baseline Sniffin'Sticks tests. The median Sniffin'Sticks test values significantly improved from pre- to post-intervention in all groups. The increase of Sniffin'Sticks test values was higher in group 1 (OC + OT) compared with groups 2 and 3 (p < 0.001) at one month after treatment but did not remain so at 2 months. Groups 1, 2 and 3, respectively, presented parosmia in 20/71 (28.2%), 9/22 (40.9%) and 42/71 (59.2%) patients. This difference was statistically significant between group 1 and 3 (p < 0.001). There were no patients with a worsening of the disease or an increase of the severity of the COVID-19 symptoms. Conclusions: The use of OCs in patients with OD related to mild COVID-19 is generally well-tolerated without any case of deterioration of symptoms. OC is associated with greater improvement in psychophysical olfactory evaluations at 1-month post-treatment but there was no difference at 2 months. Parosmia may be reduced following treatment with OC and NC. On the basis of these preliminary results, it is possible to state that considering the 2 months efficacy of OC and NC with respect to the OT alone and the risk-benefit ratio, the benefit to start a specific treatment of COVID-19 related OD cannot be demonstrated and there is a need for a randomised controlled trial to assess this further. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Psychophysical Evaluation of the Olfactory Function: European Multicenter Study on 774 COVID-19 Patients.
- Author
-
Vaira, Luigi Angelo, Lechien, Jerome R., Khalife, Mohamad, Petrocelli, Marzia, Hans, Stephane, Distinguin, Lea, Salzano, Giovanni, Cucurullo, Marco, Doneddu, Piero, Salzano, Francesco Antonio, Biglioli, Federico, Journe, Fabrice, Piana, Andrea Fausto, De Riu, Giacomo, and Saussez, Sven
- Subjects
RHINITIS ,COVID-19 ,SYMPTOMS ,SMELL disorders ,TREATMENT effectiveness - Abstract
Background: The objective evaluation of the olfactory function of coronavirus disease 2019 patients is difficult because of logistical and operator-safety problems. For this reason, in the literature, the data obtained from psychophysical tests are few and based on small case series. Methods: A multicenter, cohort study conducted in seven European hospitals between March 22 and August 20, 2020. The Sniffin-Sticks test and the Connecticut Chemosensory Clinical Research Center orthonasal olfaction test were used to objectively evaluate the olfactory function. Results: This study included 774 patients, of these 481 (62.1%) presented olfactory dysfunction (OD): 280 were hyposmic and 201 were anosmic. There was a significant difference between self-reported anosmia/hyposmia and psychophysical test results (p = 0.006). Patients with gastroesophageal disorders reported a significantly higher probability of presenting hyposmia (OR 1.86; p = 0.015) and anosmia (OR 2.425; p < 0.001). Fever, chest pain, and phlegm significantly increased the likelihood of having hyposmia but not anosmia or an olfactory disturbance. In contrast, patients with dyspnea, dysphonia, and severe-to-critical COVID-19 were significantly more likely to have no anosmia, while these symptoms had no effect on the risk of developing hyposmia or an OD. Conclusions: Psychophysical assessment represents a significantly more accurate assessment tool for olfactory function than patient self-reported clinical outcomes. Olfactory disturbances appear to be largely independent from the epidemiological and clinical characteristics of the patients. The non-association with rhinitis symptoms and the high prevalence as a presenting symptom make olfactory disturbances an important symptom in the differential diagnosis between COVID-19 and common flu. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.